trending Market Intelligence /marketintelligence/en/news-insights/trending/_a7iovcz74_svuehz0gsza2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Anthera's cystic fibrosis drug misses primary endpoint in phase 3 trial

Mining Exploration Insights – May 2020

Essential Energy Insights - May 14, 2020

Paypal Well-Positioned To Gain Share In COVID-Related Digital Payments Shift

Credit Analytics Case Study: Provogue (India) Limited and Shree Renuka Sugars


Anthera's cystic fibrosis drug misses primary endpoint in phase 3 trial

Anthera Pharmaceuticals Inc.'s Sollpura failed to meet the primary endpoint in a phase 3 clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency, the inability to properly digest food due to a lack of digestive enzymes made by the pancreas.

The drug narrowly missed the primary endpoint for change in the coefficient of fat absorption non-inferiority margin. However, the drug displayed non-inferiority in the per protocol coefficient of fat absorption and coefficient of nitrogen absorption analyses.

Coefficient of nitrogen absorption is a measure of protein digestion and absorption and is a key requirement of Anthera's planned U.S. FDA regulatory submission. The company expects to release data from the extension phase of the study in the first quarter of 2017.

Sollpura was generally well-tolerated compared to Pancreaze, although symptoms related to malabsorption were generally modestly more frequent in the Sollpura arm.

Anthera expects to start a new study with adjusted doses in 2017 and only expects a modest delay in the filing of the biologics license application around the first quarter of 2018.